Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Raymond James & Associates

Raymond James & Associates lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,631 shares of the medical equipment provider’s stock after selling 4,236 shares during the quarter. Raymond James & Associates’ holdings in Lantheus were worth $2,374,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of LNTH. Commonwealth Equity Services LLC lifted its stake in shares of Lantheus by 23.4% during the first quarter. Commonwealth Equity Services LLC now owns 15,214 shares of the medical equipment provider’s stock worth $947,000 after purchasing an additional 2,880 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Lantheus by 2.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 31,629 shares of the medical equipment provider’s stock valued at $1,969,000 after buying an additional 741 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Lantheus by 10.0% in the first quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider’s stock valued at $548,000 after buying an additional 799 shares during the last quarter. Fidelis Capital Partners LLC bought a new stake in Lantheus in the first quarter valued at about $34,000. Finally, Nordea Investment Management AB increased its holdings in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after buying an additional 14,147 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $114.96 on Wednesday. The firm has a market cap of $7.98 billion, a price-to-earnings ratio of 18.85 and a beta of 0.51. The company has a 50 day moving average of $108.41 and a 200-day moving average of $95.60. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Analysts Set New Price Targets

Several analysts recently weighed in on LNTH shares. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Transactions at Lantheus

In related news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.